Wave Life Sciences Ltd. Ordinary Shares - WVE STOCK NEWS

Wave Life Sciences reported its Q3 2024 financial results, highlighting several key achievements. The company demonstrated first-ever RNA editing in humans through its WVE-006 trial for alpha-1 antitrypsin deficiency. Cash position stands at $310.9 million as of September 30, 2024, plus additional $28 million from greenshoe option, extending runway into 2027. The company received supportive FDA feedback on WVE-003 for Huntington's disease and reported positive interim data from FORWARD-53 study of WVE-N531. Wave also announced three new GalNAc-AIMer preclinical programs for cardiometabolic diseases and plans to initiate WVE-007 clinical trial for obesity in Q1 2025.

Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and provide business updates. The event will be accessible through the company's investor relations website, with analysts able to participate in the Q&A session through a provided audio conferencing link. An archived version of the webcast will be available on the company's website following the live event.

Wave Life Sciences announced updates on its pipeline during a virtual Research Day. The company's WVE-007, a GalNAc-siRNA targeting INHBE for obesity treatment, is set to begin clinical trials in Q1 2025. New preclinical data shows WVE-007's potential as a monotherapy, in combination with GLP-1s, and for maintenance after GLP-1 discontinuation. The company also introduced three new RNA editing programs targeting PNPLA3, LDLR, and APOB for cardiometabolic diseases, with candidate selection planned for 2025. Wave aims to have five GalNAc-RNA editing or GalNAc-siRNA programs in clinical trials by 2026.

Wave Life Sciences (Nasdaq: WVE) has announced a virtual Research Day on October 30, 2024, from 10:00 a.m. to 11:30 a.m. ET. The event will showcase the company's progress in RNA medicines, including:

• Updates on their wholly owned pipeline
• Introduction of new GalNAc-conjugated RNA editing and siRNA programs
• Discussion of their clinically validated discovery and drug development platform

The company will highlight WVE-006, their RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), and WVE-007, a GalNAc-siRNA INHBE candidate for obesity treatment. Dr. Mehmet Furkan Burak, an obesity specialist from Harvard Medical School, will provide insights on the current obesity treatment landscape. The event will be accessible via webcast on Wave Life Sciences' investor relations website.

Wave Life Sciences (Nasdaq: WVE) has successfully closed its previously announced public offering, raising approximately $230 million in gross proceeds. The offering included 26,875,001 ordinary shares at $8.00 per share and pre-funded warrants to purchase 1,875,023 ordinary shares. The underwriters fully exercised their option to purchase an additional 3,750,000 ordinary shares at the same price. J.P. Morgan and Leerink Partners served as joint book-running managers, with Truist Securities and Mizuho as book-runners. The offering was made through a shelf registration statement filed with the SEC, with the final prospectus supplement and accompanying base prospectus available on the SEC's website.

Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focusing on RNA medicines, has announced its participation in the Chardan 8th Annual Genetic Medicines Conference in New York City. Paul Bolno, MD, MBA, the company's President and CEO, is scheduled for an analyst-led fireside chat on Tuesday, October 1, 2024, at 1:00 p.m. ET.

The presentation will be accessible via a live webcast on the Investor Relations page of Wave Life Sciences' website. A replay will be available for a time after the event. This conference appearance underscores Wave Life Sciences' commitment to advancing RNA medicines and engaging with the investment community.

Wave Life Sciences (Nasdaq: WVE) has announced the pricing of its upsized public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $200 million in gross proceeds. The offering includes 23,125,001 ordinary shares at $8.00 per share and pre-funded warrants to purchase up to 1,875,023 ordinary shares at $7.9999 per warrant. The company has also granted underwriters a 30-day option to purchase up to an additional 3,750,000 ordinary shares. The offering is expected to close around September 27, 2024. J.P. Morgan and Leerink Partners are acting as joint book-running managers, with Truist Securities and Mizuho as book-runners. The offering is being made through a prospectus and related supplement, with details available on the SEC's website.

Wave Life Sciences (Nasdaq: WVE) has announced a proposed public offering of $175 million in ordinary shares and pre-funded warrants. The biotechnology company, focused on RNA medicines, intends to grant underwriters a 30-day option to purchase additional ordinary shares up to 15% of the total offering. J.P. Morgan and Leerink Partners are acting as joint book-running managers, with Truist Securities and Mizuho as book-runners.

The offering is subject to market conditions and will be made through a prospectus and related supplement. A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC and available on their website. The final terms will be disclosed in a final prospectus supplement.

Wave Life Sciences announced positive interim data from the FORWARD-53 clinical trial evaluating WVE-N531 in boys with Duchenne Muscular Dystrophy (DMD) amenable to exon 53 skipping. Key findings include:

- Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%
- Meaningful improvement in serum biomarkers for muscle health
- Skeletal muscle concentrations of ~41,000 ng/g with 61-day tissue half-life
- WVE-N531 was safe and well-tolerated with only mild treatment-related adverse events

The company expects feedback on a pathway to accelerated approval and complete 48-week data in Q1 2025. Wave Life Sciences is advancing a broader DMD pipeline targeting up to 40% of boys with DMD.